Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - lysodren
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp96958c1c1275e460bebf23cdf143ad79
identifier: http://ema.europa.eu/identifier
/EU/1/04/273/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lysodren 500 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-96958c1c1275e460bebf23cdf143ad79
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/04/273/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lysodren
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
Lysodren is an antitumoral medicine.
This medicine is used for the treatment of symptoms of advanced non operable, metastatic or recurrent malignant tumours of the adrenal glands.
Do not take Lysodren
Warnings and precautions Talk to your doctor or pharmacist before taking Lysodren. You should tell your doctor if any of the following applies to you:
if you have an injury (shock, severe trauma), an infection or if you have any illness while you are taking Lysodren. Tell your doctor immediately, who may decide to temporarily stop treatment.
if you have liver problems: Tell your doctor if you develop any of the following signs and symptoms of liver problems during Lysodren treatment: itching, yellow eyes or skin, dark urine, and pain or discomfort in the right upper stomach area. Your doctor should do blood tests to check your liver function before and during treatment with Lysodren, and as clinically indicated.
if you have severe kidney problems.
if you are using any medicines mentioned below (see "Other medicines and Lysodren").
if you have gynaecological problems such as bleeding and/ or pelvic pain.
This medicine should not be handled by persons other than the patient and his/her caregivers, and especially not by pregnant women. Caregivers should wear disposable gloves when handling the tablets.
Your doctor may prescribe you some hormonal treatment (steroids) while you are taking Lysodren.
Always keep with you the Lysodren Patient Card included at the end of this leaflet.
Other medicines and Lysodren Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription.
You must not use Lysodren with medicines containing spironolactone, often used as a diuretic for heart, liver or kidney diseases.
Lysodren may interfere with several medicines. Therefore, you should tell your doctor if you are using medicines containing any of the following active substances:
Lysodren with food and drink Lysodren should preferably be taken during meals containing fat-rich food such as milk, chocolate, oil.
Pregnancy, breast-feeding and fertility Lysodren may harm the foetus. If you are pregnant or planning to become pregnant, tell your doctor. If you may become pregnant, you should use an effective contraception during treatment with Lysodren and even after stopping it, ask your doctor for advice.
You must not breast-feed while taking Lysodren and even after stopping it. Ask your doctor for advice.
Driving and using machines Lysodren has a major influence on your ability to drive and use machines. Ask your doctor for advice.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Dose and schedule The usual starting dose for adults is 2 to 3 g (4 to 6 tablets) per day. Your doctor may start treatment at higher doses such as 4 to 6 g (8 to 12 tablets).
In order to find the optimal dose for you, your doctor will monitor regularly the levels of Lysodren in your blood. Your doctor may decide to stop treatment with Lysodren temporarily or to lower the dose if you experience certain side effects.
Use in children and adolescents
The starting daily dose of Lysodren is 1.5 to 3.5 g/m2 body surface (this will be calculated by your doctor according to the weight and the size of the child). The experience in patients in this age group is very limited.
Method of administration You should swallow the tablets with a glass of water during meals containing fat-rich food. You can divide the total daily dose in two or three intakes.
If you take more Lysodren than you should Tell your doctor immediately if you have taken accidentally more Lysodren than you should or if a child has accidentally swallowed some.
If you forget to take Lysodren If you accidentally miss a dose, just take the next dose as scheduled. Do not take a double dose to make up for the forgotten one.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Lysodren can cause side effects, although not everybody gets them.
Tell your doctor immediately if you experience any of the following side effects:
These symptoms may reveal complications for which specific medication could be appropriate.
Side effects may occur with certain frequencies, which are defined as follows:
Very common side effects
Common side effects
dizziness, headache
peripheral nervous system disorders (association of sensory disorders, muscular weakness and atrophy, decrease of tendon reflex and vasomotor symptoms such as hot flushes, sweat and sleep disorders)
mental impairment (such as memory loss, concentration difficulty)
movement disorder
decrease of red blood cells (anaemia, with symptoms such as skin pallor and fatigue), decrease in blood platelets (may make you more prone to bruising and bleeding)
hepatitis (auto-immune) (may cause yellowing of the skin and eyes, dark coloured urine)
difficulty of coordinating muscles
Frequency Not Known
In children and adolescents, thyroid problems, neuro-psychological, growth retardation and one case of encephalopathy have been observed. In addition, some signs of hormonal changes (such as breast overdevelopment in males and vaginal bleeding and/or early breast development in females) have been observed.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store in the original packaging. After opening: 1 year.
Do not use this medicine after the expiry date which is stated on the carton and the bottle after EXP.
Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic medicines.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Lysodren contains
What Lysodren looks like and contents of the pack Lysodren tablets are white, biconvex, round and scored. Lysodren is available in plastic bottles of 100 tablets.
Marketing Authorisation Holder HRA Pharma Rare Diseases 200 avenue de Paris 92320 CHATILLON France
Manufacturer
Latina Pharma S.p.A. Via Murillo, 7 04013 Sermoneta (LT) Italy
or
CENTRE SPECIALITES PHARMACEUTIQUES 76-78, avenue du Midi 63800 COURNON D AUVERGNE FRANCE
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.emea.europa.eu/. There are also links to other websites about rare diseases and treatments.
This leaflet is available in all European languages on the EMA website.
LYSODREN PATIENT CARD
I am on Lysodren (mitotane) treatment
I am prone to acute adrenal insufficiency
In case I need emergency care,
adequate precautionary measures should be taken
The name of my Doctor is:
.. Phone: .
For information on the product, please contact: HRA Pharma Rare Diseases Tel: + 33 1 40 33 93 medinfo-rd@hra-pharma.com
Entry 1 - fullUrl = Composition/composition-en-96958c1c1275e460bebf23cdf143ad79
Resource Composition:
Generated Narrative: Composition composition-en-96958c1c1275e460bebf23cdf143ad79
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/04/273/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lysodren
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp96958c1c1275e460bebf23cdf143ad79
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp96958c1c1275e460bebf23cdf143ad79
identifier:
http://ema.europa.eu/identifier
/EU/1/04/273/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lysodren 500 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en